Search

Your search keyword '"Taramasso L"' showing total 272 results

Search Constraints

Start Over You searched for: Author "Taramasso L" Remove constraint Author: "Taramasso L"
272 results on '"Taramasso L"'

Search Results

1. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

2. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

3. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

4. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

6. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects

7. Pillars of long-term antiretroviral therapy success

8. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

9. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

10. Incident diabetes in course of antiretroviral therapy

11. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda

12. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

13. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

15. Weight Gain: A Possible Side Effect of All Antiretrovirals

16. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children

17. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

18. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort

19. Computed tomography assessment of PEEP-induced alveolar recruitment in patients with severe COVID-19 pneumonia

20. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

21. Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19

22. Evaluation of HIV transmission clusters among natives and foreigners living in Italy

23. Reversibility of Central Nervous System Adverse Events in Course of Art

24. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

25. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

26. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

27. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

29. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

30. The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study

31. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

32. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

33. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

34. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

35. Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study

37. Factors associated with hospital admission for COVID-19 in HIV patients

38. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani

39. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity

41. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients

42. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study

43. Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine?

44. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

45. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients.

46. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

47. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

48. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

49. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

50. Missed opportunities to prevent mother-to-child transmission of HIV in Italy

Catalog

Books, media, physical & digital resources